Naturewise Biotech & Medicals (ROCO:4732) Total Debt per Share: NT$0.66 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4732 Naturewise Biotech & Medicals Corp ROCO:4732
62 GF Score
Price NT$18.20
GF Value NT$19.64
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Naturewise Biotech & Medicals Total Debt per Share?

Naturewise Biotech & Medicals ROCO:4732 +4.00% 62 Total Debt per Share is NT$0.66 as of Jun. 2026. GuruFocus rates ROCO:4732 with a GF Score™ of 62/100 and a GF Value™ of NT$19.64 (Fairly Valued). The stock has 4 warning signs investors should review.

NT$0.66 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Naturewise Biotech & Medicals's Total Debt Per Share for the quarter that ended in Jun. 2026 was NT$0.66.

Naturewise Biotech & Medicals Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Naturewise Biotech & Medicals's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Naturewise Biotech & Medicals Total Debt per Share Chart

Naturewise Biotech & Medicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.10 0.22 0.08 0.26

Naturewise Biotech & Medicals Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.08 0.15 0.26 0.66
ROCO:4732
62GF Score
Naturewise Biotech & Medicals Corp ROCO:4732
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Naturewise Biotech & Medicals Total Debt per Share Calculation

Naturewise Biotech & Medicals's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(6.7+6.0)/48.2
=0.26

Naturewise Biotech & Medicals's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(4.7+26.9)/48.3
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of NT$0.66 mean?
Naturewise Biotech & Medicals (ROCO:4732) has a Total Debt per Share of NT$0.66 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Naturewise Biotech & Medicals and its competitors.
Is Naturewise Biotech & Medicals' Total Debt per Share too high?
Naturewise Biotech & Medicals' current Total Debt per Share is NT$0.66. Overall, Naturewise Biotech & Medicals has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Total Debt per Share compare to VRTX and REGN?
Naturewise Biotech & Medicals' Total Debt per Share of NT$0.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current Total Debt per Share is NT$0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.64, compared to a current price of NT$18.20 — trading 7.3% below its estimated fair value. The current Total Debt per Share is NT$0.66. Naturewise Biotech & Medicals' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Total Debt per Share is NT$0.66 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?

Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued. The current stock price of NT$18.20 is trading 7.3% below its estimated GF Value™ of NT$19.64. GuruFocus considers Naturewise Biotech & Medicals to be Fairly Valued.

Key valuation signals for ROCO:4732:

  • Total Debt per Share: NT$0.66
  • GF Value™: NT$19.64 vs. price of NT$18.20 (7.3% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Naturewise Biotech & Medicals Business Description

Address No. 36, Bade Road, 6th Floor, Section 3, Songshan District, Taipei, TWN, 105
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
62GF Score

Get the complete analysis for ROCO:4732

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.20
Price
NT$19.64
GF Value